These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 38891871)
1. D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside. Barabássy Á; Dombi ZB; Németh G Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891871 [TBL] [Abstract][Full Text] [Related]
2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. Citrome L Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212 [TBL] [Abstract][Full Text] [Related]
3. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Gründer G Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978 [TBL] [Abstract][Full Text] [Related]
4. Dopamine D3 Receptors: From Bench to Bedside. Gonda X; Tarazi FI Neuropsychopharmacol Hung; 2021 Jun; 23(2):272-280. PubMed ID: 34342419 [TBL] [Abstract][Full Text] [Related]
5. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990 [TBL] [Abstract][Full Text] [Related]
6. The role of dopamine D Calabrese F; Tarazi FI; Racagni G; Riva MA CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452 [TBL] [Abstract][Full Text] [Related]
7. Cariprazine for the Treatment of Bipolar Disorder. Findlay LJ; El-Mallakh PL; El-Mallakh RS Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102 [TBL] [Abstract][Full Text] [Related]
8. The Role of Dopamine D Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of cariprazine. Stahl SM CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157 [TBL] [Abstract][Full Text] [Related]
10. Cariprazine: First Global Approval. McCormack PL Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944 [TBL] [Abstract][Full Text] [Related]
11. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597 [TBL] [Abstract][Full Text] [Related]
12. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders. De Deurwaerdère P Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339 [TBL] [Abstract][Full Text] [Related]
13. Cariprazine for the treatment of bipolar depression: a review. Ragguett RM; McIntyre RS Expert Rev Neurother; 2019 Apr; 19(4):317-323. PubMed ID: 30753085 [TBL] [Abstract][Full Text] [Related]
14. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167 [TBL] [Abstract][Full Text] [Related]
15. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Citrome L Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833 [TBL] [Abstract][Full Text] [Related]
16. Cariprazine in Bipolar Depression and Mania: State of the Art. Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291 [TBL] [Abstract][Full Text] [Related]
17. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Veselinović T; Paulzen M; Gründer G Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719 [TBL] [Abstract][Full Text] [Related]
18. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Citrome L Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832 [TBL] [Abstract][Full Text] [Related]
19. Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential. Koziej S; Kowalczyk E; Soroka E Med Sci Monit; 2024 Sep; 30():e945411. PubMed ID: 39300746 [TBL] [Abstract][Full Text] [Related]